Assessing the role of colonic and other anatomical sites uptake by [18F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors

FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients

(2022) Marc-André Léger et al.   SEMINARS IN NUCLEAR MEDICINE

Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors

(2022) Sara Elena Rebuzzi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

(2022) Giuseppe L. Banna et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Prognostic value of lactate dehydrogenase in non-small cell lung cancer patients with brain metastases: a retrospective cohort study

(2022) Shuting Wang et al.   Journal of Thoracic Disease

Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis

(2022) Tao Ling et al.   Frontiers in Immunology

The Role of Tumor Inflammatory Microenvironment in Lung Cancer

(2021) Zhaofeng Tan et al.   Frontiers in Pharmacology

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

(2021) G.L. Banna et al.   ESMO Open

TMB or not TMB as a biomarker: That is the question

(2021) Alfredo Addeo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Lung cancer

(2021) Alesha A Thai et al.   LANCET

Prognostic Value of MTV and TLG of 18F-FDG PET in Patients with Stage I and II Non-Small-Cell Lung Cancer: a Meta-Analysis

(2021) Weibo Wen et al.   Contrast Media & Molecular Imaging

Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy

(2021) Ela Delikgoz Soykut et al.   Journal of Medical Imaging and Radiation Oncology

The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?

(2021) Byeongsang Oh et al.   Cancers

Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non–small cell lung cancer patients

(2020) Yun-Mei Shi et al.   NUCLEAR MEDICINE COMMUNICATIONS

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)

(2020) Ye Li et al.   Frontiers in Oncology

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

(2020) Taiki Hakozaki et al.   Cancer Immunology Research

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

(2020) Giuseppe Luigi Banna et al.   Translational Lung Cancer Research

Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer

(2020) Pamela Vernocchi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

(2020) Denis L. Jardim et al.   CANCER CELL

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

(2019) Deborah B Doroshow et al.   CLINICAL CANCER RESEARCH

Tumor Mutation Burden—From Hopes to Doubts

(2019) Alfredo Addeo et al.   JAMA Oncology

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab

(2019) Jingjing Liu et al.   JOURNAL OF CLINICAL LABORATORY ANALYSIS

Blocking inflammation to improve immunotherapy of advanced cancer

(2019) Antonio Macciò et al.   IMMUNOLOGY

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

(2018) Giuseppe Luigi Banna et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Laura Mezquita et al.   JAMA Oncology

Cytokines in clinical cancer immunotherapy

(2018) Pedro Berraondo et al.   BRITISH JOURNAL OF CANCER

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

(2017) Frédéric Bigot et al.   EUROPEAN JOURNAL OF CANCER

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer

(2016) Giuseppe Luigi Banna et al.   ONCOLOGY

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

(2008) H-T Arkenau et al.   BRITISH JOURNAL OF CANCER

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE